C

Coherus BioSciences
D

CHRS

1.25500
USD
-0.02
(-1.18%)
مغلق
حجم التداول
108,080
الربح لكل سهم
-1
العائد الربحي
-
P/E
-14
حجم السوق
144,592,826
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ARWR
    -2.890
    (-13.49%)
    18.540 USD
    B
    BLUE
    -0.04270
    (-11.74%)
    0.32090 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    K
    KRYS
    -6.865
    (-3.87%)
    170.590 USD
    M
    MGTA
    0
    (0%)
    0.000000 USD
    N
    NTLA
    -1.165
    (-7.71%)
    13.955 USD
    R
    RGNX
    -1.51500
    (-13.60%)
    9.62500 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    VRTX
    VRTX
    -18.53
    (-3.83%)
    464.69 USD
    المزيد
الأخبار

العنوان: Coherus BioSciences

القطاع: Healthcare
الصناعة: Biotechnology
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.